CriteriaCaixa, the investment arm of Spain’s ‘la Caixa’ Banking Foundation, is rebranding its VC operations and deploying €300 million into Iberian BioTech and DeepTech startups. The move signals a strategic pivot from broad early-stage bets to concentrated plays in sectors where Spain and Portugal punch above their weight: life sciences, AI-driven therapeutics, and advanced materials. CriteriaCaixa manages €12 billion in assets, giving it dry powder to outlast thinner VCs in a capital-scarce Europe.

This is late validation that Iberia’s science startups are no longer a niche. Madrid and Barcelona now host 15% of Europe’s biotech unicorns, yet local capital has been scattered. CriteriaCaixa’s €300 million—roughly 2.5% of its AUM—is a vote of confidence in domestic IP, not just imports. The focus on BioTech and DeepTech avoids the crowded SaaS lane where US VCs still outbid everyone. It also aligns with EU subsidies flowing into strategic autonomy, where health tech and semiconductors are priority.

Winners: Iberian founders in BioTech and DeepTech gain a patient, well-capitalized local backer. CriteriaCaixa gets first-mover advantage in a region where US VCs like a16z and General Catalyst are only now opening scouting offices. Losers: Pan-European VCs without a Iberian thesis may find deal flow squeezed. Traditional Spanish banks lack the risk appetite to compete here.

Watch for CriteriaCaixa to lead or co-lead €15-30M Series B rounds in Spanish and Portuguese startups like Ona Therapeutics (€40M raised) or Aelix Therapeutics. Expect co-investment from EU’s EIC Fund, which has €10B earmarked for deep tech. If CriteriaCaixa’s deployment pace exceeds €50M per year, it will force other Iberian institutions to follow.